JPWO2021118924A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021118924A5 JPWO2021118924A5 JP2022535461A JP2022535461A JPWO2021118924A5 JP WO2021118924 A5 JPWO2021118924 A5 JP WO2021118924A5 JP 2022535461 A JP2022535461 A JP 2022535461A JP 2022535461 A JP2022535461 A JP 2022535461A JP WO2021118924 A5 JPWO2021118924 A5 JP WO2021118924A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- signaling inhibitor
- inhibitor
- kit
- egfr signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 27
- 102000001301 EGF receptor Human genes 0.000 claims 26
- 108060006698 EGF receptor Proteins 0.000 claims 26
- 230000011664 signaling Effects 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 5
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 claims 4
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims 4
- 108091054455 MAP kinase family Proteins 0.000 claims 4
- 102000043136 MAP kinase family Human genes 0.000 claims 4
- 102000038030 PI3Ks Human genes 0.000 claims 4
- 108091007960 PI3Ks Proteins 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 108091008611 Protein Kinase B Proteins 0.000 claims 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 4
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims 4
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims 4
- 230000022131 cell cycle Effects 0.000 claims 4
- 229960002465 dabrafenib Drugs 0.000 claims 4
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 229960004066 trametinib Drugs 0.000 claims 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 4
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 3
- 102000042838 JAK family Human genes 0.000 claims 3
- 108091082332 JAK family Proteins 0.000 claims 3
- 229960003862 vemurafenib Drugs 0.000 claims 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 3
- WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical group CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000003716 rejuvenation Effects 0.000 claims 2
- 239000011885 synergistic combination Substances 0.000 claims 2
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- -1 NCK Proteins 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962947059P | 2019-12-12 | 2019-12-12 | |
US62/947,059 | 2019-12-12 | ||
PCT/US2020/063595 WO2021118924A2 (en) | 2019-12-12 | 2020-12-07 | Compositions and methods for the prevention and treatment of hearing loss |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023506768A JP2023506768A (en) | 2023-02-20 |
JPWO2021118924A5 true JPWO2021118924A5 (en) | 2023-11-29 |
Family
ID=76329057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022535461A Pending JP2023506768A (en) | 2019-12-12 | 2020-12-07 | Compositions and methods for prevention and treatment of hearing loss |
Country Status (5)
Country | Link |
---|---|
US (2) | US11433073B2 (en) |
EP (1) | EP4073102A4 (en) |
JP (1) | JP2023506768A (en) |
CN (1) | CN114981298A (en) |
WO (1) | WO2021118924A2 (en) |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US20090142337A1 (en) | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
EP2046330A2 (en) | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
CA2667108C (en) | 2006-11-10 | 2015-10-20 | Telefonaktiebolaget Lm Ericsson (Publ) | Edge node for a network domain |
DK3560498T3 (en) | 2009-10-16 | 2022-11-14 | Novartis Ag | COMBINATION COMPRISING A MEK INHIBITOR AND A B-RAF INHIBITOR |
EP3299464B1 (en) | 2010-05-26 | 2019-10-02 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
KR101909433B1 (en) | 2011-12-02 | 2018-10-18 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | Agent for reducing adverse side effects of kinase inhibitor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
WO2014009318A1 (en) | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer |
WO2014009319A1 (en) | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | Indolinone derivatives anticancer compounds |
EP2903597B1 (en) | 2012-10-03 | 2019-12-18 | Exosome Diagnostics Inc. | Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions |
WO2014107718A2 (en) | 2013-01-07 | 2014-07-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Heat shock protein (hsp) inhibition and monitoring effectiveness thereof |
US20160089371A1 (en) | 2013-03-15 | 2016-03-31 | Intellikine, Llc | Combination of Kinase Inhibitors and Uses Thereof |
US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
CN104211692B (en) | 2013-06-04 | 2019-05-24 | 广东东阳光药业有限公司 | Derivative as Ou Ruola kinase inhibitor |
CN104447701B (en) | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | Pyrazole derivatives and application thereof |
EP3068435A1 (en) | 2013-11-13 | 2016-09-21 | Novartis AG | Mtor inhibitors for enhancing the immune response |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
WO2015104292A2 (en) | 2014-01-07 | 2015-07-16 | Biomedical Research Foundation Of The Academy Of Athens | Compounds for use in treating or preventing cancerous diseases |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
HUE046008T2 (en) | 2014-07-17 | 2020-02-28 | Sunshine Lake Pharma Co Ltd | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)urea derivatives and related compounds as flt3 inhibitors for treating cancer |
JP2017527547A (en) | 2014-08-13 | 2017-09-21 | エピザイム,インコーポレイティド | Combination therapy to treat cancer |
WO2016043874A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Combination therapy for treating cancer |
EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
EP3936141A3 (en) | 2015-01-23 | 2022-03-23 | Erasmus University Rotterdam Medical Center | Anti-senescence compounds and uses thereof |
MY186133A (en) | 2015-03-02 | 2021-06-24 | Rigel Pharmaceuticals Inc | Tgf-? inhibitors |
EP3265448B1 (en) | 2015-03-03 | 2021-12-29 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
WO2016160881A1 (en) | 2015-04-01 | 2016-10-06 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN107801378A (en) | 2015-05-22 | 2018-03-13 | 普莱希科公司 | For treating the PLX 8394 or PLX 7904 of the related diseases of BRAF V600 |
EP3786164A1 (en) | 2015-06-18 | 2021-03-03 | Ting Therapeutics LLC | Methods and compositions for the prevention and treatment of hearing loss |
WO2017031363A2 (en) | 2015-08-18 | 2017-02-23 | Aspyrian Therapeutics, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
US10765665B2 (en) * | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
CA3007462C (en) | 2015-12-07 | 2023-10-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017162510A1 (en) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Substituted quinazolinone compounds for the treatment of proliferative diseases |
CN107345231A (en) * | 2016-05-05 | 2017-11-14 | 江苏命码生物科技有限公司 | A kind of siRNA for suppressing EGFR gene expression and its precursor and application |
CA3025486A1 (en) | 2016-05-25 | 2017-11-30 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
US20190209532A1 (en) | 2016-08-10 | 2019-07-11 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
MX2019002731A (en) | 2016-09-08 | 2019-10-02 | Curematch Inc | Optimizing therapeutic options in personalized medicine. |
KR20190088513A (en) | 2016-11-23 | 2019-07-26 | 케모센트릭스, 인크. | Treatment of local segmental glomerulosclerosis |
CN110545846A (en) | 2017-02-23 | 2019-12-06 | 乐天医药生技股份有限公司 | Therapeutic compositions for photoimmunotherapy and related methods |
WO2018192416A1 (en) | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
WO2018204226A1 (en) * | 2017-05-03 | 2018-11-08 | St. Jude Children's Research Hospital | Compositions and methods for prevention and treatment of hearing loss |
JP2020520380A (en) | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | Remedy |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
WO2019103984A1 (en) | 2017-11-22 | 2019-05-31 | Memorial Sloan Kettering Cancer Center | Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof |
GB201802307D0 (en) * | 2018-02-13 | 2018-03-28 | Vib Vzw | CD36 antagonists for use in melanoma treatment |
EP3643305A1 (en) | 2018-10-25 | 2020-04-29 | Universität für Bodenkultur Wien | Compositions for the elimination of senescent cells |
TWI688379B (en) | 2018-11-29 | 2020-03-21 | 財團法人亞洲大學 | Joint loosening equipment |
US20200170972A1 (en) | 2018-11-30 | 2020-06-04 | Strongbridge Dublin Limited | Methods of treating disease with dichlorphenamide |
CN111477466B (en) | 2019-01-23 | 2021-04-02 | 清华大学 | Charging method of self-charging super capacitor |
US11857551B1 (en) * | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
-
2020
- 2020-12-07 WO PCT/US2020/063595 patent/WO2021118924A2/en active Search and Examination
- 2020-12-07 CN CN202080086445.XA patent/CN114981298A/en active Pending
- 2020-12-07 EP EP20900420.9A patent/EP4073102A4/en active Pending
- 2020-12-07 JP JP2022535461A patent/JP2023506768A/en active Pending
-
2022
- 2022-01-21 US US17/580,755 patent/US11433073B2/en active Active
- 2022-05-04 US US17/736,330 patent/US20220265660A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Quock et al. | Possible involvement of nitric oxide in chlordiazepoxide-induced anxiolysis in mice | |
JP2020518642A5 (en) | ||
NO331166B1 (en) | Inhibitors of tyrosine kinases, process for their preparation, pharmaceutical preparation and use of the compounds | |
ATE390135T1 (en) | METHOD OF USE AND COMPOSITIONS CONTAINING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASTIC SYNDROME | |
van der Veldt et al. | Targeted therapy for renal cell cancer: current perspectives | |
EP2210606A3 (en) | Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | |
US20050209186A1 (en) | Method for treating chronic myelogenous leukemia | |
RU2004129281A (en) | COATED STENTS CONTAINING N- {5- [4- (4-METHYLPIPERASINOMETHYL) BENZOYLAMIDO] -2-METHYLPHENYL} -4- (3-PYRIDYL) - 2-PYRI MIDINAMIN | |
JP2005517040A5 (en) | ||
Davids et al. | Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies | |
RU2006128504A (en) | SYNTHETIC ANALGETIC PRODUCT AND METHOD OF TREATMENT BASED ON THIS PRODUCT | |
JPWO2020022507A5 (en) | ||
JPWO2021118924A5 (en) | ||
Fung et al. | The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery | |
Nisar et al. | Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis | |
WO2021118924A4 (en) | Compositions and methods for the prevention and treatment of hearing loss | |
ZA202307921B (en) | Combination of raf inhibitor and mek inhibitor | |
Varma et al. | Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma | |
BRPI0418743A (en) | methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit | |
JP2020536890A (en) | Combination of MDM2 Inhibitors and ERK Inhibitors to Treat Cancer | |
Jefferson et al. | The pharmacotherapy of obsessive-compulsive disorder | |
CL2022002317A1 (en) | Methods of treating primary progressive multiple sclerosis using a bruton tyrosine kinase inhibitor. | |
MXPA03007743A (en) | Combination of a taxane and a cyclin-dependent kinase. | |
MX2022013482A (en) | Compounds useful for inhibiting ret kinase. | |
Wollheim et al. | Treatment of systemic sclerosis in 1988 |